References
- Al HS, Ramos C. Evidence required by FDA to approve drugs for hematological malignancies in pivotal clinical trials. Leuk Lymphoma. 2021. DOI:https://doi.org/10.1080/10428194.2021.1876872
- Buckley SA, Percival ME, Othus M, et al. A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leuk Lymphoma. 2019;60(4):1023–1029.
- Del Paggio JC, Tannock IF. The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis. Lancet Oncol. 2019;20(8):1065–1069.
- Berger JO, Berry DA. Statistical analysis and the illusion of objectivity. Am Sci. 1988;76:159–165.
- Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740.
- Astellas Reports XOSPATA (gilteritinib) in combination with azacitidine did not meet endpoint of overall survival in newly diagnosed FLT3 mutation-positive acute myeloid leukemia patients ineligible for intensive induction chemotherapy [Internet]. Tokyo: Astellas. 2020; [updated 2020 Dec 21] [cited 2021 Feb 5]. Available from: https://www.astellas.com/us/news/5306
- Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia [Internet]. Princeton (NJ): Bristol Myers Squibb. 2020; [updated 2020 Aug 25] [cited 2021 Feb 5]. Available from: https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-IDHENTIFY-Trial-in-Patients-with-Relapsed-or-Refractory-Acute-Myeloid-Leukemia/default.aspx
- Unger JM, Barlow WE, Ramsey SD, et al. The Scientific impact of positive and negative phase 3 cancer clinical trials. JAMA Oncol. 2016;2(7):875–881.
- Hilal T, Sonbol MB, Prasad V. Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US Food and Drug Administration. JAMA Oncol. 2019;5(6):887–892.
- Soni PD, Hartman HE, Dess RT, et al. Comparison of population-based observational studies with randomized trials in oncology. J Clin Oncol. 2019;37(14):1209–1216.
- Huang X, Ning J, Li Y, et al. Using short-term response information to facilitate adaptive randomization for survival clinical trials. Stat Med. 2009;28(12):1680–1689.
- Giles FJ, Kantarjian HM, Cortes JE, et al. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol. 2003;21(9):1722–1727.
- Vaughn JE, Shankaran V, Walter RB. Trends in clinical benefits and costs of novel therapeutics in AML: at what price does progress come? Curr Hematol Malig Rep. 2019;14(3):171–178.